1536-4844/asset/IBD_left.gif?v=1&s=9aca2b5041534c51cac4bb66560294c77a457a07)
1536-4844/asset/IBD_right.gif?v=1&s=402e3e241083497ae622916e85e47f64138255a4)
Original Article
You have free access to this content
Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy
Article first published online: 26 SEP 2011
DOI: 10.1002/ibd.21824
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.
Additional Information
How to Cite
Vaughn, B. P., Doherty, G. A., Gautam, S., Moss, A. C. and Cheifetz, A. S. (2012), Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. Inflamm Bowel Dis, 18: 1057–1063. doi: 10.1002/ibd.21824
Publication History
- Issue published online: 17 MAY 2012
- Article first published online: 26 SEP 2011
- Manuscript Accepted: 12 JUN 2011
- Manuscript Received: 16 MAY 2011
REFERENCES
- 1, , . Management of Crohn's disease in adults. Am J Gastroenterol. 2009; 104: 465–483.
- 2(CDC) CfDCaP. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha—California, 2002–2003. MMWR Morb Mortal Wkly Rep. 2004; 53: 683–686.
- 3. Modulation of infection with histoplasma capsulatum by inhibition of tumor necrosis factor-alpha activity. Clin Infect Dis. 2005; 41( suppl 3): S204–207.
- 4, . Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy. Drugs. 2009; 69: 1403–1415.
- 5, , , et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002; 46: 2565–2570.
- 6, , , et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001; 345: 1098–1104.
- 7, , , et al. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis. 2005; 41( suppl 3): S194–198.
- 8. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis. 2008; 8: 601–611.
- 9, , , et al. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol. 2006; 12: 974–976.
- 10, , , et al. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol. 2008; 43: 397–401.
- 11, , , et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut. 2004; 53: 1363–1365.
- 12, . Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010; 105: 501–523.
- 13, , , et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006; 130: 940–987.
- 14, , , et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol. 2004; 2: 309–313.
- 15, , , et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008; 59: 762–784.
- 16, , , et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohn's Colitis. 2010; 4: 28–62.
- 17, , , et al. The European (ECCO) Consensus on infection in IBD: what does it change for the clinician? Gut. 2009; 58: 1313–1315.
- 18, . Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006; 43: 209–220.
- 19, , , et al. Regional survey of tuberculosis risk assessment in rheumatology outpatients commencing anti-TNF-alpha treatment in relation to British Thoracic Society guidelines. Clin Med. 2009; 9: 225–230.
- 20, , , et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol. 2008; 103: 2799–2806.Direct Link:
- 21, , , et al. AGA technical review on perianal Crohn's disease. Gastroenterology. 2003; 125: 1508–1530.